Humacyte, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
HUMA$0.59+29.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
CONSOLIDATED BALANCE SHEETS
(in thousands except for share and per share amounts)
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $44,937 | $80,448 |
| Prepaid expenses and other current assets | 2,922 | 2,830 |
| Total current assets | 47,859 | 83,278 |
| Restricted cash | 50,209 | 209 |
| Property and equipment, net | 23,063 | 26,791 |
| Finance lease right-of-use assets, net | 15,490 | 17,313 |
| Other long-term assets | 1,251 | 632 |
| Total assets | $137,872 | $128,223 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $4,490 | $6,490 |
| Accrued expenses | 11,424 | 9,340 |
| Finance lease obligation, current portion | 2,917 | 2,560 |
| Other current liabilities | 1,123 | 53 |
| Total current liabilities | 19,954 | 18,443 |
| Contingent Earnout Liability | 70,961 | 37,916 |
| Revenue interest liability | 63,354 | 38,600 |
| Common stock warrant liabilities | 19,254 | 78 |
| Finance lease obligation, net of current portion | 13,620 | 16,293 |
| Contingent derivative liability | 2,415 | 2,636 |
| Other long-term liabilities | 983 | 711 |
| Total liabilities | 190,541 | 114,677 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity (deficit) | ||
| Preferred stock, $0.0001 par value; 20,000,000 shares designated as of December 31, 2024 and 2023; 0 shares issued and outstanding as of December 31, 2024 and 2023 | — | — |
| Common stock, $0.0001 par value; 250,000,000 shares authorized as of December 31, 2024 and 2023; 130,027,509 and 103,673,728 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 13 | 10 |
| Additional paid-in capital | 633,333 | 550,850 |
| Accumulated deficit | (686,015) | (537,314) |
| Total stockholders’ equity (deficit) | (52,669) | 13,546 |
| Total liabilities and stockholders’ equity (deficit) | $137,872 | $128,223 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.